www.klinickafarmakologie.cz / Klin Farmakol Farm. 2024;38(3):112-117 / KLINICKÁ FARMAKOLOGIE A FARMACIE 117 HLAVNÍ TÉMA Biologické účinky pomocných látek používaných u intravenózně podávaných léčiv 44. Kim SH, Kwon JC, Park C, et al. Therapeutic drug monitoring and safety of intravenous voriconazole formulated with sulfobutylether β-cyclodextrin in haematological patients with renal impairment. Mycoses. 2016;59(10):644-651. 45. Lilly CM, Welch VL, Mayer T, et al. Evaluation of intravenous voriconazole in patients with compromised renal function. BMC Infect Dis. 2013;13:14. 46. Oude Lashof AML, Sobel JD, Ruhnke M, et al. Safety and Tolerability of Voriconazole in Patients with Baseline Renal Insufficiency and Candidemia. Antimicrob Agents Chemother. 2012;56(6):3133-3137. 47. Neofytos D, Lombardi LR, Shields RK, et al. Administration of Voriconazole in Patients With Renal Dysfunction. Clinical Infectious Diseases. 2012;54(7):913-921. 48. Yasu T, Konuma T, Kuroda S, et al. Effect of Cumulative Intravenous Voriconazole Dose on Renal Function in Hematological Patients. Antimicrob Agents Chemother. 2018;62(9):e00507-18. 49. Food and Drug Administration [on-line]. ERAXIS® (anidulafungin) for injection, for intravenous use. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/ label/2020/021632027_S029lbl.pdf. 50. Food and Drug Administration [on-line]. CELLCEPT Intravenous (mycophenolate mofetil) for injection, for intravenous use. Available from: https://www.accessdata.fda.gov/ drugsatfda_docs/label/2022/050722s049s051,050723s049s 051,050758s047s049lbl.pdf.
RkJQdWJsaXNoZXIy NDA4Mjc=